Unlearn.AI, a San Francisco, CA-based developer of a machine-learning powered platform that creates Digital Twins to populate Intelligent Control Arms in clinical studies, raised $12m in Series A financing.
The round was led by 8VC with participation from existing investors DCVC, DCVC Bio and Mubadala Capital Ventures. In conjunction with the funding, 8VC Principal Francisco Gimenez, Ph.D., has joined the Unlearn Board of Directors.
The company intends to use the funds to continue to expand operations and its business reach.
Founded in 2017 by Charles K. Fisher, Ph.D., founder and CEO, Unlearn.AI leverages its proprietary DiGenesis™ platform which processes historical clinical trial datasets from thousands of patients to build the disease-specific machine learning models used to create Digital Twins and their corresponding virtual medical records. Digital Twin records are longitudinal and include demographic information, common lab tests, and endpoints and/or biomarkers that look identical to actual patient records in a clinical trial. The company’s initial focus is on neurological diseases, starting with Alzheimer’s Disease and Multiple Sclerosis.